Our Partners
Read More
New Company and Collaboration To Develop Novel Therapeutics Including Vonoprazan for the Treatment of Acid-Related Disorders in North America and Europe Cambridge, Mass. and Menlo […]
RC-01 represents a new class of antibiotics in development for the treatment of serious antibiotic-resistant infections Menlo Park, April 1, 2019 — Recida Therapeutics, Inc. announced […]
